Determination of the Antineoplastic Activity of Berberine Isolated from *Tinospora cordifolia* in Swiss Albino Mice Transplanted with Ehrlich Ascites Carcinoma

Ganesh Chandra Jagetia* and SK Rao

1Department of Zoology, Mizoram University, India
2Department of Pharmacognosy, C U Shah College of Pharmacy & Research, India

Submission: May 04, 2017; Published: June 30, 2017

*Corresponding author: Ganesh Chandra Jagetia, Department of Zoology, Mizoram University, Aizwal-796 004, India, Tel: 91-389-2330724/2330227; Email: gc.jagetia@gmail.com

Abstract

Natural products have attracted the attention of humans for healthcare since time immemorial. The anticancer activity of berberine chloride (BCL), an alkaloid isolated from the dichloromethane extract of *Tinospora cordifolia*, was studied in mice transplanted with Ehrlich ascites carcinoma (EAC) by injecting 10mg/kg BCL on 1, 3, 6, 9, 12 or 15 days, (stage I, II, III, IV, V and VI) after EAC inoculation. The data analysis revealed that maximum tumor free survivors (58.3%) at 30 days were observed in mice receiving BCL on second day of tumorization. The administration of BCL on day 3 and 4 after tumor inoculation also increased the tumor free survivors at 30 days. Despite this increase in survival, no long term survivors (>60 days) could be reported at any of the stages evaluated. The BCL treatment was more effective than cyclophosphamide, the positive control, which was effective only at stage I and II, however, the number of tumor free survivors on day 30 was lesser than the BCL treatment. The analysis of lipid peroxidation and GSH contents in EAC cells showed a time dependent depletion in the GSH activity up to 9h post-treatment and a marginal elevation thereafter. This depletion in GSH was accompanied by a drastic elevation in lipid peroxidation with a maximum rise at 9h post-treatment and a gradual decline thereafter. Our study demonstrates that BCL treatment caused tumor regression and increased tumor free survival by reducing the GSH concentration and increasing the lipid peroxidation.

Keywords: Mice; Ehrlich ascites carcinoma; Survival; Glutathione; Lipid peroxidation

Introduction

The chemotherapy is one of the important modalities to treat cancer and it is especially helpful in the advance stages of cancer treatment. Chemotherapy is either used alone or in conjunction with radiation and/or surgery to treat difficult neoplasia. The term chemotherapy was coined by Paul Ehrlich, in 1907 against the drug/s used to treat infection, however now it is synonymous with the drugs that are used for cancer treatment [1,2]. It is well known that most of the chemotherapeutic drugs act on proliferating cancer cells by triggering DNA damage in these cells and this not only results in chemotherapy resistance after repeated uses of these agents but also leads to the development of second malignancies in the fortunate survivors [3-5]. Despite the availability of several treatment modalities in modern medicine, the mortality rate after cancer treatment have not come down and remains at the level of 1950, especially for solid tumors [6]. Further cancer chemotherapy is associated with severe side effect in the various other organs that are devoid of cancer [7-9]. This indicates the need of alternative drugs which are highly effective and less or negligibly toxic to normal cells.

Plants and natural products have played a crucial role in the human healthcare and the herbal preparations and natural products have been used to treat cancer since time immemorial [10]. Ayurveda, the Indian system of medicine mainly uses plant based drugs or formulations to treat different human health disorders including cancer. The plants and natural products still continue to play important role as complementary and alternative medicine apart from the standard modern chemotherapy in the management of cancer. Medicines derived from plants have played a pivotal role in healthcare of ancient cultures and also continue to play a significant role even in modern times [11]. It is also well known that most effective modern chemotherapeutic drugs like vinca alkaloids, epipodophyllotoxins, camptothecins taxanes, bleomycins and doxorubicin have been derived from plants/natural products before their actual chemical synthesis began.
Berberine is an isquinoline alkaloid and is synthesized by several plants including Tinospora cordifolia. It has been reported to possess diverse pharmacological actions including antibacterial, antifungal, anticholesterolase, anti diarrheal, anti inflammatory, antioxidant, hepatoprotective, antiarrhythmic, and antihypertensive activities [16-22]. Preclinical studies have reported the chemopreventive and antineoplastic activities of berberine in vivo and in vitro earlier [23-25]. Berberine is active against diabetes, coronary artery diseases, fatty liver disease, diarrhea, gastroenteritis, obesity, hyperlipidemia, hypertension, Alzheimer’s disease, metabolic syndrome, and polycystic ovary [26,27]. Clinically berberine has been reported to improve the cardiac performance in patients presenting heart failure and it exerted a direct depressive action on myocardial vasculature and smooth musculature [28]. An improvement in left ventricular ejection fraction and ventricular premature complexes has been reported in the patients with chronic congestive heart failure after administration of 1.2 to 2g of berberine daily [29]. Clinical studies have shown that berberine treatment was effective in type 2 diabetes in human subjects [30-32]. Berberine administration has been clinically very effective in the treatment of dyslipidemia, dementia, non fatty liver disease, hyperlipidemia, and ocular Behcet’s disease [33-38]. Recent studies from our laboratory have shown that berberine is cytotoxic to HeLa cells and the cytotoxic effect may be due to triggering of molecular DNA damage into the cellular DNA and was also found to increase the effect of radiation in these cells [39,40]. The studies on the antineoplastic action of berberine on the various stages of tumor development in vivo are lacking. This stimulated us to investigate the antineoplastic activity of 10mg/kg b. wt. berberine in mice transplanted with Ehrlich ascites carcinoma on various stages of tumor progression.

Materials and Methods

Drugs and chemical

Berberine chloride (BCL), thiobarbituric acid, trichloroacetic acid, 5,5-dithio2-nitrobenzoic acid (DTNB), glutathione reduced, and tetraethoxypropane were purchased from Sigma Chemical Co. St. Louis, USA whereas other routine chemicals were procured from Ranbaxy Fine Chemicals, Mumbai, India. Cyclophosphamide was supplied by Biochem Pharmaceutical Industries, Mumbai, India.

Animal care and handling

The animal care and handling were undertaken according to the guidelines of World Health Organization, Geneva, Switzerland and the INSA (Indian National Science Academy, New Delhi). Female Swiss albino mice aged eight to ten-weeks and weighing 30 to 36g were culled from an inbred colony maintained under the controlled conditions of temperature (23±2 °C), humidity (50±5%) and 12 hours of light and dark cycle, respectively. The animals were allowed free access to sterile food and water. Usually four animal were housed in a sterile polypropylene cage containing sterile paddy husk (procured locally) as bedding throughout the experiments. The study was approved by the institutional animal ethical committee.

Tumor model

Ehrlich ascites carcinoma (EAC) was procured from the Cancer Research Institute (ACTREC), Mumbai, India. The EAC was propagated and maintained by serial intraperitoneal transplantation of 10⁵ viable EAC cells in female mice in an aseptic environment. The day of tumor inoculation was designated as day 0.

Preparation of drug and mode of administration

Cyclophosphamide (CPA) was dissolved in sterile physiological saline (SPS), whereas berberine chloride was dissolved in hot double distilled water. The SPS, CPA or BCL were administered intraperitoneally unless otherwise stated.

Experimental

The antineoplastic activity of BCL was determined by dividing the EAC transplanted mice into the following groups:

a) SPS group: The animals of this group received 0.3 to 0.36ml of sterile physiological saline (SPS).

b) CPA group: This group of animals received 25mg/kg b. wt. of CPA once daily for nine consecutive days and served as concurrent positive control [24].

c) BCL group: The animals of this group were administered with a single dose of 10mg/kg BCL once daily, for nine consecutive days [24].

Anticancer activity determination

A separate experiment was carried out to evaluate the antineoplastic action of BCL, where grouping and other conditions were exactly similar to that described above, except that the animals of CPA and BCA groups were administered with these drugs after 1, 3, 6, 9, 12 and 15 days of tumor transplantation and for reasons of clarity these days have been arbitrarily designated as stage I, II, III, IV, V and VI, respectively.

The animals of all the groups were monitored regularly for alteration in body weight, signs of toxicity and mortality. The weight of animals was recorded every third day up to 30 days after tumor inoculation in all the groups. A 33% of drug related deaths or a weight loss of 5g per mouse was considered as an index of toxicity [41]. The animal survival was monitored daily up to 120 days, since the survival of animals up to 120 days is roughly equivalent to 5 years survival in man [42]. The tumor response...
was assessed on the basis of median survival time and tumor free survival. The median survival time (MST), and the average survival time (AST) were calculated from the animals dying within 120 days and those surviving 120 days were excluded from it.

The MST and AST were calculated as follows:

\[
\text{MST} = \frac{\text{First death} + \text{last death in the group}}{2}
\]

\[
\text{AST} = \frac{\text{Sum of animal death on different days}}{\text{Number of animals}}
\]

The increase in median life span (% IMLS) and increase in average life span (% IALS) were also calculated using the following formulae:

\[
\text{IMLS} = \frac{\text{MST of treated mice} - \text{MST of control} \times 100}{\text{MST of control}}
\]

\[
\text{IALS} = \frac{\text{AST of treated mice} - \text{AST of control} \times 100}{\text{AST of control}}
\]

**Biochemical analyses**

A separate experiment was performed to estimate glutathione and lipid peroxidation in the tumor cells. The grouping and other condition were essentially similar to that described in experimental section except that the animals were inoculated with EAC cells and the tumor was allowed to grow for six days so as to get a reasonable volume for aspiration of cells. On seventh day, the tumor bearing animals were administered only once with SPS or CPA or BCL as the case may be.

Four animals from each group were sacrificed at 0, 1.5, 3, 6, 9, 12, 15, 18 or 24h after the BCL or CPA administration. The tumor cells were aspirated in aseptic condition and were washed with SPS thrice. The cells were counted under an inverted microscope (Labovert microscope, Ernst Leitz, Wetzlar GmbH, Germany) and 1 x 10^6 cells were sonicated (Virsonic, Virtis, NY, USA) and processed for the estimation of glutathione and lipid peroxidation assays as follows:

**Glutathione (GSH):** GSH concentration was measured by the method of Moron et al. [43]. Briefly, proteins were precipitated by 25% TCA, centrifuged and the supernatant was collected. The supernatant was mixed with 0.2M sodium phosphate buffer pH 8.0 and 0.06mM DTNB and incubated for 10 minutes at room temperature. The absorbance of the sample/s was read against the blank at 412nm in a UV-Visible double beam spectrophotometer (Shimadzu UV-260, Shimadzu Corporation, Tokyo, Japan) and the GSH concentration was calculated from the standard curve.

**Lipid peroxidation (LOO):** LOO was measured by the method of Beuege & Aust [44]. Briefly, the homogenate was mixed with TCA-TBA-HCl and heated for 15min in a boiling water bath. After centrifugation the absorbance was recorded at 535nm using a UV-Visible double beam spectrophotometer. The lipid peroxidation has been expressed as TBARS in nmol per 10^6 cells. The concentration of LOO in the sample was determined against the standard curve of MDA (Malonaldehyde).

**Statistical analyses:** The statistical significance between the treatments was determined using the “Z” test for the survival studies [45], whereas the student’s ‘t’ test was used for the biochemical estimations. A p value of <0.05 was considered statistically significant. All the data are expressed as mean ±SEM (standard error of the mean).

**Results**

Table 1: Antineoplastic activity of 10mg/kg BCL in mice transplanted with Ehrlich ascites carcinoma.

| Treatment | Survival | Percent Survival (day) |
|-----------|----------|------------------------|
|           | MST      | IMLS | AST | IALS | 30   | 60   | 90 | 120 |
| SPS       | 19       | 18   | -   | -    | 0    | 0    | 0  | 0   |
| BCI I     | 35.5     | 86.8 | 35.2| 95.5 | 30c  | 0    | 0  | 0   |
| CPA I     | 29       | 57.9 | 28  | 55.8 | 16.7 | 0    | 0  | 0   |
| BCI II    | 37       | 84.7 | 33.7| 87.2 | 58.3b| 0    | 0  | 0   |
| CPA II    | 26.5     | 39.5 | 26.3| 46.6 | 8.3  | 0    | 0  | 0   |
| BCI III   | 33       | 73.7 | 32.1| 78.3 | 33.3c| 0    | 0  | 0   |
| CPA III   | 24       | 26.3 | 23.1| 28.5 | 0    | 0    | 0  | 0   |
| BCI IV    | 29.2     | 31.6 | 23.2| 28.9 | 18   | 0    | 0  | 0   |
| CPA IV    | 21.5     | 13   | 21.1| 17.4 | 0    | 0    | 0  | 0   |
| BCI V     | 21.5     | 13.1 | 20.3| 11.3 | 0    | 0    | 0  | 0   |
| CPA V     | 19       | -    | 18.9| 5.3  | 0    | 0    | 0  | 0   |
| BCI VI    | 19       | -    | 18.9| 5.0  | 0    | 0    | 0  | 0   |
| CPA VI    | 18.5     | -    | 18.2| 1.6  | 0    | 0    | 0  | 0   |

a = p < 0.0001; b = p < 0.001; c = p < 0.002; d = p < 0.05 (when compared with SPS)

SPS: Sterile Physiological Saline; CPA: Cyclophosphamide; BCL: Berberine Chloride
The anticancer activity of BCL was determined by injecting 10mg/kg BCL, which was found to be the optimum dose for antineoplastic action [24]. The mice transplanted with EAC tumor did not show any regression until the end of the experiment where all the animals receiving SPS died within 18-19 days (Table 1). The stage specific evaluation of the anticancer activity of BCL was carried out in tumor bearing animals on 1, 3, 6, 9, 12 or 15 days, (stages I, II, III, IV, V and VI, respectively) by administering a single dose of 10mg/kg BCL once daily or 25mg/kg CPA for nine days, consecutively at stages I, II, III, IV, V or VI. The administration of 25mg/kg CPA exerted a significant anticancer activity only when administered in the early stages of tumor development, which is validated by the body weight changes (Figure 1). None of the animals treated with CPA at various stages of tumor development survived beyond 30 days post-tumor cell inoculation (Table 1).

The survival of EAC mice declined in a stage specific manner. The MST for the tumor bearing animal that received CPA at stages I, II, III, IV, V and VI was approximately 29, 26, 24, 21, 19 and 18 days, respectively (Table 1), while AST was approximately 29, 26, 24, 21, 19 and 18 for stage I, II, III, IV, V and VI, respectively. An approximate IMLS, of 58, 39, 26 and 13% was observed for stages I, II, III and IV, respectively. The administration of CPA at the end stages (i.e. V and VI) proved ineffective in increasing the IMLS. The IALS also decreased in a stage specific manner in the CPA group and it was approximately 56, 47, 28, 17 and 6%, for stage I, II, III, IV and VI, respectively (Table 1).

The treatment of mice with 10mg/kg BCL at stages I, II, III, IV or V resulted in an increase in the MST approximately up to 35, 37, 33, 29 and 21 days, whereas administration of BCL raised the AST up to 35, 34, 32, 23 and 20 days, respectively (Table 1). The IMLS and IALS also increased after BCL treatment depending on the stage of the tumor at which the drug was administered. The IMLS and IALS declined depending on the treatment stage and the lowest values were observed for stage V. The IMLS of approximately 87, 85, 74, 32 and 13% and the IALS of 95, 87, 78, 29 and 11% were recorded for stage I, II, III, IV and V, respectively after 10mg/kg BCL treatment when compared to CPA treatment (Table 1). The stage specific evaluation showed that BCL was effective up to stage IV and a maximum effect was observed for stage II, where approximately 58% animals survived until 30 days. However no tumor free survivors could be observed beyond 30 days post tumor inoculation (Figure 1). Despite this fact the BCL treatment was more effective than CPA, the positive control as the number of survivors was higher than the CPA group (Table 1).

**Biochemical estimations**

**Glutathione (GSH):** The GSH concentration remained unaltered with time in EAC mice treated with SPS (Figure 2). The administration of CPA or BCL into EAC mice caused a time dependent decline in the GSH concentration in EAC cells till a nadir was reached at 9h post-treatment. A further increase in the assay time caused an elevation in GSH contents at 12h post-treatment, which continued to rise until 18h post-treatment thereafter a steady state was reached (Figure 2). The GSH concentration

The results of anticancer activity and biochemical assays are presented in Table 1 and Figure 1, 2 & 3 as mean ±SEM.

**Anticancer activity determination**
was marginally higher in the BCL group when compared to CPA treatment (Figure 2). Despite the fact that CPA and BCL treatment alleviated GSH concentration the differences were not statistically significant.

**Lipid peroxidation (LOO):** The lipid peroxidation remained unaltered with time in EAC mice treated with SPS (Figure 3). Treatment of EAC mice with CPA or BCL caused a time-dependent increase in the LOO of tumor cells until a peak was reached at 9 and 12h post-treatment for BCL and CPA treatments, respectively. This increase in LOO in CPA was statistically significant (p < 0.01). A further increase in the assay time caused a decline in LOO at 15h post-treatment, however the LOO was significantly (P<0.05) higher in the CPA treated group, when compared to the SPS treatment. Thereafter a steady state was reached (Figure 3). BCL treatment brought the LOO level to almost SPS level by 24h post treatment (Figure 3).

**Discussion**

Humans have always relied on nature for survival since ancient times and it has been our main source of food, protection, clothing, transportation and medicines [46,47]. Natural products have been an important source of several medicines including chemotherapeutic agents [12,48]. Plant-derived compounds, in particular have a special place in anticancer therapy. Some of the modern chemotherapeutic agents derived from plants or their semi synthetic counterparts currently available in the market for use in a clinical setting are paclitaxel (Taxol), bisindole alkaloids (vinblastine, vincristine, vinorelbine, vinflunine), podophyllotoxin (etoposide, teniposide, and etoposide phosphate) and camptothecins (irinotecan and topotecan), a natural product precursor for water-soluble derivatives. Apart from these many other new plant derived products have been approved by FDA for the treatment of various cancers [12]. This clearly indicates that natural products will continue to be extremely important as sources of medicinal agents. The natural products have found direct medicinal application as drug entities and many others can serve as chemical models or templates for the design, synthesis, and semisynthesis of novel substances for treating human diseases. Although there are some new approaches to drug discovery, such as combinatorial chemistry and computer-based molecular modeling design, none of them can replace the important role of natural products in drug discovery and development. Therefore, it was desired to screen the antineoplastic activity of berberine in Swiss albino mice transplanted with Ehrlich ascites carcinoma.

Human beings suffering from various neoplastic disorders come for clinical evaluation and treatment in the different stages of tumor development. Therefore, an effective anticancer agent should be able to kill tumor cells efficiently during any stage of the tumor [49]. An effort has been made to screen the antineoplastic activity of 10mg/kg BCL at various stages of tumor development with respect to the efficacy of 25mg/kg of CPA. The results from the stage specific evaluation show that both BCL and CPA retarded the increase in body weight gain in EAC mice due to tumor development and increased the survival during the early stages effectively. This may be due to the effective killing of EAC cells during the early stages of tumor development by BCL. Berberine has been shown to have an anticancer effect on mice bearing EAC cells during the early stages of tumor development [24]. A similar effect was observed earlier where 5 and 10mg/kg berberine retarded the tumor weight gain in mice transplanted with B16 murine melanoma and it also inhibited the proliferation of these cells in vitro [50]. Berberine has been reported to inhibit cell proliferation and cell survival in HeLa cells in a concentration dependent manner recently [39,40]. Likewise, berberine has been also reported to exert cytotoxic effect on Saos-2, MG-63, BC-1, BCBL-1, TY-1, U937, FaDu, SW480, and HT-29 human cells of different tissue origin [51-56]. The berberine was ineffective during mid and late stages of tumor development. The studies of the anticancer activity of natural products at different stages of tumor development are scanty. Echitamine, Alstonia scholaris, and Aphananrix polysychhya have been reported to inhibit EAC growth when administered in different stages of tumor development earlier [49,56,57].

Natural medicines have gained popularity over synthetic drugs in recent years with the belief that they are much safer and have led to the tremendous growth of phytopharmaceutical usage [58]. Increased concentration of GSH in the tumor cells have been reported to make the tumor refractory to treatment, whereas depletion of glutathione has been reported to enhance the cell death and apoptosis of the tumor cells along with the loss of essential sulfhydryl groups that result in an alteration of the calcium homeostasis and eventually loss of cell viability [59,60]. The lipid peroxidation is another important event related to cell death and has been reported to cause severe impairment of membrane function through increased membrane permeability and membrane protein oxidation and eventually cell death by damaging the important cellular macromolecules like DNA, RNA and proteins [61,62]. A similar effect has been observed in the present study where BCL has reduced GSH concentration and elevated the LOO considerably. The increase and reduction in LOO and GSH respectively by BCL may have damaged the DNA of EAC cells thereby bringing effective tumor cell kill. The changes in the membrane fluidity coupled with the damage to DNA by BCL may have been responsible for the killing of tumor cells and prolongation of life span in EAC mice during early stages.

The exact mechanism of cell killing by berberine in the present study is not very clear. It is possible that berberine may have utilized multiple pathways to kill EAC tumor cells in mice. The berberine may interact with DNA and RNA forming complex with them [63]. The triggering of DNA damage by berberine treatment may be one of the important causes of cell death that subsequently increased the life span of tumor bearing animals. Our earlier studies have shown that berberine causes molecular DNA damage in HeLa cells [39,40]. The other mechanism may be the inhibition of topoisomerase II by BCL, which may have stabilized the transient DNA double strand breaks leading to cell death.

How to cite this article: GC Jagetia, SK Rao. Determination of the Antineoplastic Activity of Berberine Isolated from Tinospora cordifolia in Swiss Albino Mice Transplanted with Ehrlich Ascites Carcinoma. J Tumor Med Prev. 2017; 1(3): 555561. DOI: 10.19080/JTMP.2017.01.555561
Berberine has been reported to inhibit topoisomerase-II [26]. The presence of berberine may have suppressed the activation of nuclear factor kappa B (NF-κB) involved in providing survival advantage to cancer cells [64]. This would have led to the inhibition of antiapoptotic proteins and activation of apoptotic machinery by upregulating p53 expression and inhibiting the expression of Bcl-2 and COX-II causing tumor cell death [63,65]. The berberine may have triggered apoptosis in tumor cells by activating caspase 3, 7, 8 and 9 along with FasL, and TNF-related apoptosis-inducing ligands, and proapoptotic proteins including Bax, Bad, and Apaf-1 followed by the suppression the anti-apoptotic factors, such as Bcl-2 and Bcl-xl as reported earlier [54]. Berberine has been also reported to inhibit EGFR, AKT, MAPK, and STAT3 which play a crucial role in cell proliferation [63,65]. Cell cycle arrest could be another mechanism of retardation in cell proliferation as berberine has been found to arrest the cells in G1 and G2 phase and suppress cyclin expression [66]. The suppression of Nr2f2 may have also contributed in the cell killing effect of berberine as it enhanced LOO and reduced GSH in the present study.

**Conclusion**

Berberine has killed EAC cells resulting in the increased survival of tumor bearing mice treated with 10mg/kg b. wt. BCL. It was most effective when it was administered on day 2 after tumor transplantation. Berberine significantly increased LOO and reduced the GSH contents. Berberine may have killed the tumor cells by inducing molecular DNA damage or forming complexes with DNA and RNA. The inhibition of topoisomerase II, NF-κB, EGFR, AKT, MAPK, STAT3, Bcl-2 and Bcl-xl may have played an important role at molecular level to bring the death of EAC cells after berberine treatment. Berberine may have also activated caspase 3, 7, 8 and 9 along with FasL, Bax, Bad, and Apaf-1 causing apoptotic death of tumor cells.

**Acknowledgement**

This work was carried out under the grants from the Council of Scientific and Industrial Research, and Indian Council of Medical Research, Govt. of India, New Delhi, India.

**References**

1. Parascondola J (2008) The theoretical basis of Paul Ehrlich’s chemotherapy. J History Med 36(1): 19-43.
2. DeVita VT, Chu E (2008) A History of Cancer Chemotherapy. Cancer Res 68(21): 8645-8653.
3. Bouwman E, Jonker J (2012) The effects of deregulated DNA damage signaling on cancer chemotherapy response and resistance. Nature Rev Cancer 12(9): 587-598.
4. Woods D, Turchi J (2013) Chemotherapy induced DNA damage response: Convergence of drugs and pathways. Cancer Biol Ther 14(5): 379-389.
5. Morton LM, Swerdlow AJ, Schaapveld M, Ramadan S, Hodgson DC, et al. (2014) Current knowledge and future research directions in treatment-related second primary malignancies. J Clin Oncol 12(1): 5-17.
6. Siegel RL, Miller KD, Jemal A (2016) Cancer Statistics, 2016. CA Cancer J Clin 66(1): 7-30.
7. Pedersen B, Koktved DP, Nielsen LL (2013) Living with side effects from cancer treatment: a challenge to target information. Scand J Caring Sci 27(3): 715-723.
8. Iwamoto T (2013) Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull 36(5): 715-718.
9. Zhang X, Chen WW, Huang WJ (2017) Chemotherapy-induced peripheral neuropathy. Biomed Rep 6: 267-271.
10. Baguley BC (2002) A brief history of cancer chemotherapy. In: Anticancer Drug Development. Academic Press, New York, p. 1-11.
11. Greenlee H, Neugut AI, Fakci L, Hillyer GC, Buono D, et al. (2016) Association between complementary and alternative medicine use and breast cancer chemotherapy initiation: the Breast Cancer Quality of Care (BQUAL) study. JAMA Oncol 2(9): 1170-1176.
12. Kinghorn AD, De Blanco EJC, Lucas DM, Rakotondraibe HL, Orjala J, et al. (2016) Discovery of anticancer agents of diverse natural origin. Anticancer Res 36(11): 5623-5637.
13. Wargovich MJ, Woods C, Hollis DM, Zander ME (2001) Herbals, cancer prevention and health. J Nutr 131(11): 3034S-3036S.
14. Huebner J, Marienfeld S, Abbenhart C, Ulrich C, Muenstedt K, et al. (2014) Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anticancer Res 34(1): 39-48.
15. Jagetia GC, Rao SK (2017) Berberinechloride, an isoquinoline alkaloid induces cytotoxicity in cultured HeLa Cells. Adv Biotechnol Biochem 2017: J120.
16. Kuo CL, Chou CC, Yung BY (1995) Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett 93(2): 193-200.
17. Yang IW, Chou CC, Yung BYM (1996) Dose-dependent effects of berberine on cell cycle pause and apoptosis of H460/c3T3 cells. Naunyn-Schmiedeberg’s Arch Pharmacol 354(2): 102-108.
18. Williamson EM (2001) Synergy and other interactions in phytotherapies. Phytomedicine 8(5): 401-409.
19. Singh A, Duggal S, Kaur N, Singh J (2010) Berberine: Alkaloid with wide spectrum of pharmacological activities. J Nat Prod 3(2010): 64-75.
20. Nadkarni KM, Nadkarni AK (1976) Indian Materia Medica, Vol 1 (3rd edn.), Popular Prakasan Pvt Ltd, Mumbai, India.
21. Zhao TH, Wang X, Rimando AM, Che C (1991) Folkloric medicinal plants: Tinospora sagittata var. cravaniana and Mahonia bealei. Planta Med 57(5): 505.
22. Chopra RN, Nayar SL, Chopra IC (1996) Glossary of Indian Medicinal Plants: Publications & Information Directorate, Govt. of India, New Delhi.
23. Anis KV, Rajeshkumar NV, Kuttan R (2001) Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 53(5): 763-768.
24. Chopra IC (1996) Berberine: Alkaloid with wide spectrum of pharmacological activities. J Nat Prod 3(2010): 64-75.
25. Anis KV, Rajeshkumar NV, Kuttan R (2001) Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 53(5): 763-768.
like dementia: Involvement of acetylcholinesterase and cell death. Neurotoxicology 57: 241-250.

28. Neto FR (1993) Electropharmacological effects of berberine on canine cardiac Purkinje fibres and ventricular muscle and atrial muscle of the rabbit. Br J Pharmacol 108(2): 534-537.

29. Zeng XL, Zeng XJ, Li YY (2003) Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 92(2): 173-176.

30. Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57(5): 712-717.

31. Zhang H, Wei J, Xue R, Wu JD, Zhao W, et al. (2010) Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59(9): 285-292.

32. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, et al. (2015) Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 161: 69-81.

33. Hu Y, Ehlé EA, Kittelsrud J, Ronan PJ, Munger K, et al. (2012) Lipid-lowering effect of Berberine in human subjects and rats. Phytomedicine 19(10): 861-867.

34. Chang X, Wang Z, Zhang J, Yan H, Bian H, et al. (2016) Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med 14: 266.

35. Di Pierro F, Putignano P, Ferrare T, Raiola C, Rapacioli G, et al. (2016) Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silibum marianum, and monocolin K and KA in patients with dyslipidemia. Clin Pharmacol 9: 1-7.

36. Huang M, Chen S, Liang Y, Gou Y (2016) The role of berberine in the multi-target treatment of smnile dementia. Curr Top Med Chem 16(8): 867-873.

37. Koppenn LM, Whittaker A, Rosea A, Beckett RD (2017) Efficacy of berberine alone and in combination for the treatment of hyperlipidemia: A systematic review. J Ethnopharmacol 210: 1-13.

38. Yang Y, Wang Q, Xie M, Liu P, Qi X, et al. (2017) Berberine exerts an anti-inflammatory role in ocular Behcet’s disease. Mol Med Rep 15(1): 97-102.

39. Jagetia GC, Rao SK (2015) Isoquinoline alkaloid berberine exerts its antineoplastic activity by inducing molecular DNA damage in HeLa cells: A comet assay study. Biotechnol and Medicine 7(1): 223.

40. Jagetia GC, Rao SK (2016) The isoquinoline alkaloid berberine augments radiation effect by enhancing the DNA damage at molecular level in HeLa cells irradiated with various doses of γ-radiation: Correlation between DNA damage and clonogenicity. J Mol Genet Med 10: 235.

41. Geran RI, Greenberg NH, Mac Donald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3(2): 1-103.

42. Nias AHW (1990) Radiation Biology. In: Sikorski K & Halnan KE (eds.). Treatment of cancer. Chapman and Hall Medical, London, UK, p. 53-75.

43. Monon MS, Depeurie JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochem Biophys Acta 562(1): 67-78.

44. Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52: 302-310.

45. Abramowitz M, Stegun IA (1972) Handbook of Mathematical Functions. Library of Congress Catalog Card Number 65-12253. Dover Publications, Inc. New York, p. 925.
66. Tan W, Lu J, Huang M, Li Y, Chen M, et al. (2011) Anti-cancer natural products isolated from Chinese medicinal herbs. Chinese Med 6(1): 27.